长期使用阿司匹林和心力衰竭发病率:患者一级综合分析研究
Mianli Xiao1, Zailing Xing1, Douglas Schocken2
1Department of Epidemiology, College of Public Health, University of South Florida, Tampa, Florida, USA.
The American journal of medicine
|September 2, 2025
概括
在没有心血管疾病的患者中,慢性阿司匹林使用与心力衰竭的风险增加有关. 相反,避免服用阿司匹林与心力衰竭的风险降低有关.
科学领域:
- 心血管医学
- 流行病学
- 药理学
背景情况:
- 长期使用阿司匹林对心力衰竭的影响尚不清楚.
- 之前的研究没有评估阿司匹林的使用是对心力衰竭风险的时间依赖.
研究的目的:
- 评估长期使用阿司匹林对心力衰竭的发生率的影响.
- 评估持续使用阿司匹林与从未使用阿司匹林相关的心力衰竭的风险.
主要方法:
- 来自四项前性队列研究的数据分析,其中包括26941名心力衰竭风险的参与者.
- 对发生心力衰竭的长度随访,收集阿司匹林使用和风险因素的时间依赖数据.
- 使用参数式g公式估计假设的阿司匹林使用干预措施的影响.
主要成果:
- 在平均14.8年的时间里,记录了5899例心力衰竭病例.
- 持续使用阿司匹林与7% 的心力衰竭风险增加有关 (RR1. 07).
- 从未使用阿司匹林与6% 的心力衰竭风险降低有关 (RR 0. 94).
结论:
- 长期使用阿司匹林会增加没有心血管疾病的患者心力衰竭的风险.
- 这些发现突显了长期使用阿司匹林对心脏健康的潜在不利影响.
- 该g公式提供了一个可靠的方法来估计时间依赖的暴露效应.
相关概念视频
Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure I: Introduction
52
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
52
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure VII: Nursing Interventions
139
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
139


